Indian Pharma Market (IPM) is consolidating in prescriptions with a growth of 2% in the MAT period and growth of 1% over the corresponding period.
The top 15 companies have a prescription share of 37.4% and the next 15 companies have a prescription share of 13.1%. Thus, the top 30 companies account to over 50% of IPM.
Sun Pharma and Abbott have the highest effective prescriber base of 93% each, followed by Cipla with 90%, Mankind Pharma and Alkem Labs with 89%
Sun Pharma has the highest Per Capita Prescriptions of 18.9, followed by Mankind Pharma with 17.3; and, Alkem Labs with 13.9
IPM : Broad Therapeutic Distribution
Gastro Intestinal (GI) is the leading Broad Therapy Classification (BTC) with 21% prescription share and consolidation of 3% over the corresponding period and further a consolidation of 7% over the previous period.
Cardiovascular, CNS, Diabetes and Obesity are the other rapidly consolidating major BTCs.